Diprosalik, ointment for external use 30 g
Category
Psoriasis
Scope of the drug
Dermatology
Release form
Ointment
Manufacturer country
Belgium
Package quantity, pcs
one
Diprosalik ointment d / nar.
approx.
tube 30g No. 1
Name ENG
DIPROSALIC
Clinical and pharmacological group
Drug with anti-inflammatory and keratolytic action for external use
ATX code
Betamethasone in combination with other drugs
Dosage
0.05% + 3% x 30g
Structure
1 g: betamethasone dipropionate 640 mcg, which corresponds to the content of betamethasone 500 mcg, salicylic acid 30 mg
Excipients: liquid paraffin - 100 mg, petroleum jelly - 869.36 mg.
Indications
To reduce the inflammatory manifestations of dry and hyperkeratic dermatoses sensitive to GCS therapy, including:
psoriasis
chronic atopic dermatitis
neurodermatitis (chronic lichen simplex)
lichen planus
eczema (coin-shaped, hand eczema, eczematous dermatitis)
dyshidrosis
seborrheic dermatitis of the scalp
ichthyosis and ichthyosis lesions.
INN / Active ingredient
Betamethasone + salicylic acid
Contraindications
Hypersensitivity to any component of the drug.
Storage conditions and periods
At a temperature not higher than 25 degrees.
Expiration date: 5 years
Specifications
Category
Psoriasis
Scope of the drug
Dermatology
Release form
Ointment
Manufacturer country
Belgium
Package quantity, pcs
one
Scope of application
Dermatology
Minimum age from
2 years old
Way of introduction
Outwardly
,
On the skin
Vacation conditions
Without recipe
Brand name
Diprosalik
The amount of the dosage form in the primary package
30 g
Primary packaging type
Aluminum tube
Type of consumer packaging
Pack of cardboard
Anatomical and therapeutic characteristics
D07XC01 Betamethasone, in combination with other drugs
Dosage form
Ointment for external use
Packaging
Box
Expiration date in days
1825
The target audience
Adult
Package weight, g
60
Mode of application
:
Diprosalik ointment should be applied in a thin layer 2 times a day - in the morning and at night, completely covering the affected skin.
In some patients, a supportive effect can be achieved with less frequent applications.
Pharmaco-therapeutic group
:
Topical glucocorticosteroid + keratolytic agent
Dosage (volume) of the substance in the preparation
:
1 g: betamethasone dipropionate 640 mcg, which corresponds to the content of betamethasone 500 mcg, salicylic acid 30 mg